Adrestia Therapeutics is a seed startup. Status: possibledead.
Based in the United States, Adrestia Therapeutics is a startup founded in 2018. Its most recent tracked round is Seed. Brouky records 2 investors associated with the company.
Adrestia Therapeutics develops targeted cancer therapies by focusing on synthetic lethality approaches to enable precision medicine treatments.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.